Section Review Central & Peripheral Nervous Systems: α₁-Adrenoceptor antagonists as treatments for benign prostatic hyperplasia

References

• MCNEAL J: Pathology of benign prostatic hyperplasia: Insight into etiology. Urol. Clin. North Am. (1990) 17:477–486.
   PubMed Web of Science ®Google Scholar
• HIEBLE JP, CAINE M, ZALAZNIK E: In vitro characterisation of alpha-adrenoceptors in human prostate. Eur. J. Pharmac. (1985) 107:111–117.
   PubMed Web of Science ®Google Scholar
• CHAPPLE CR, AUBREY ML, JAMES S, GREENGRASS PM, BURNSTOCK G, TURNER-WARWICK RT, MILROY EJ, DAVEY, MJ: Characterisation of human prostatic-ad-renoceptors using pharmacology receptor binding and localisation. Br. J. Urol. (1989) 63:487–496.
   PubMedGoogle Scholar
• FURAYA S, KUMAMOTO Y, YOKOYAMA E, TSUKAMOTO T, IZUMI T, ABIKO Y: Alpha-adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy. J. Urol. (1982) 128:836–839.
   PubMed Web of Science ®Google Scholar
• CAINE M, PERLBERG S, MERETYK S: A placebo-controlled, double-blind study of the effect of phenoxybenzamine In benign prostatic obstruction. Br.J. DI:V. (1978) 50:551–556.
   Web of Science ®Google Scholar
• HEDLUND H, ANDERSSON ICE, EK A: Effects of prazosin in patients with benign prostatic obstruction. j Um!. (1983) 130:275–278.
   Google Scholar
• BUZELIN JM., HERBERT M, BLONDIN P, AND THE PRAZALF GROUP: Alpha-blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: compara-tive study with prazosin. Br. J. (Ira (1993) 72:922–927.
   Web of Science ®Google Scholar
• KAWABE K, UENO A, TAKIMOTO Y, ASO Y, KATO II, YM617 CLINICAL STUDY GROUP: Use of an alpha-1-blocker, YM617, in the treatment of benign prostatic hypertrophy. J. Urol. (1990) 144:908–912.
   PubMed Web of Science ®Google Scholar
• JANKNEGT RA, CHAPPLE CR: Efficacy and safety of the alpha-1 blocker doxazosin in the treatment of benign prostatic hyperplasia. Analysis of 5 studies. Eur. Urol. (1993) 24:319–325.
   PubMed Web of Science ®Google Scholar
• FORD APD, WILLIAMS TJ, BLUE DR, CLARICE DE: 04-Adrenoceptor dassification: sharpening Occam's razor. Trends Pharmacol. Sci. (1994) 15:167–170.
   PubMed Web of Science ®Google Scholar
• Overview of current ai-adrenoceptor subype nomenclature: sub-sequently adopted by IUPHAR nomenclature committee.
   Google Scholar
• HIEBLE JP, BYLUND DB, CLARKE DE, EIKENBURG DC, LANGER SZ, LEFKOWITZ Rj, MINNEMAN KP, RUFFOLO RR, Jr.: International Union of Pharmacology X. Recom-mendation for nomenclature of alpha-l-adrenoceptors consensus update. Pharm. Rev. (1995) 47:267–270.
   Google Scholar
• Currently defined nomenclature.
   Google Scholar
• CLARKE DE, FORD APDW, WILLIAMS TJ, BONHAUS DW,VIMONT RL, BLUE DR, Jr.: Pharmacological evidence for the equivalence of the alpha-1A-adrenoceptor of rat and the cloned bovine alpha-1C-adrenoceptor: A revised alpha-l-adrenoceptor classification scheme. Pharma-cology Communications (1995) 6:9–14.
   Google Scholar
• BLUE DR, BONHAUS DW, FORD APDW, PFISTER JR, SFIARIF NA, SHIEH IA, VIMONT RL, WILLIAMS TJ, CLARKE DE: Functional evidence equating the pharmacologi-cally-defined alit and cloned alc-adrenoceptor: studies In the isolated perfused kidney of rat. Br. J. Pharmacol. (1995) 115:283–294.
   PubMed Web of Science ®Google Scholar
• MICHEL A.D, LOURY DN, WHITING RL: Identification ofa single al-adrenoceptor corresponding to the alA subtype in rat submaxillary gland. Br. J. Pharmacol. (1989) 98:883–889.
   PubMed Web of Science ®Google Scholar
• MICHEL MC, INSEL PA: Comparison of cloned and phar-macologically defined rat tissue al-adrenoceptor sub-types. Naunyn-Schmiedeberg's Arch. Pharmacol. (1994) 350:136–142.
   Google Scholar
• KENNY BA, CHALMERS DH, PHILPOTT PC, NAYOR AM:Characterisation of an am-adrenoceptor mediating the contractile response of rat aorta to noradrenaline. Br. J. Pharmacol. (1995) 115:981–986.
   PubMed Web of Science ®Google Scholar
• FLAVAHAN NA, VANHOUITE PM: as-Adrenoceptor sub-classification in vascular smooth muscle. Trends Phar-macol. Sci. (1986) 7:347–349.
   Web of Science ®Google Scholar
• MURAMATSU I, OHMURA T, KIGOSHI S, HASHIMOTO S, OSHITA M: Pharmacological subclassification of al-ad-renoceptors in vascular smooth muscle. Br. J. Pharma-col. (1990) 99:197–201.
   PubMed Web of Science ®Google Scholar
• Evidence for additional subtypes of ai-adrenoceptor based on functional studies in vascular smooth muscle.
   Google Scholar
• HIRASAWA A, SHIBATA K, HORIE K, TAKEI Y, OBIKA K,TANAKA T, MURAMOTO N, TAKAGAKI K, YANO J, TSUJI-MOTO G: Cloning, functional expression and tissue distribution of human alpha-1C-adrenoceptor splice variants. FEBS Lett. (1995) 363:256–260.
   PubMed Web of Science ®Google Scholar
• PRICE DT, SCHWINN DA, LOMASNEY JW, ALLEN LF,CARON MG LEFKOWITZ RJ: Identification, quantitation, and localization of mRNA for three distinct alpha' adrenergic subtypes in human prostate. J Um!. (1993) 150:546–551.
   Google Scholar
• FORRAY C, BARD JA, WETZEL JM, CHIU G, SHAPIRO E, TANG R, LEPOR H, IIARTIG PR, WEINSHANK RL, BRANCIIEK TA, GLUCHOWSKI C: The alpha-l-adreno-ceptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha-1C subtype. MoL Pharmacol. (1994) 45:703–708.
   PubMed Web of Science ®Google Scholar
• Pharmacological evidence suggesting that human prostate contracts via atA-adrenoceptors.
   Google Scholar
• SMITH DJ, CHAPPLE CR, MARSHALL I, BURT RP. ANDERS-SON PO, GREENGRASS PM, WYLLIE MG: Human alpha-1C-adrenoceptors: functional characterisation in the human prostate. J. Urn!. (1993) 149:434A.
   Google Scholar
• LEPOR H, TANG R, SHAPIRO E: The alpha-adrenoceptormediating the tension of human prostatic smooth mus-cle. Prostate (1993) 22:301–307.
   PubMed Web of Science ®Google Scholar
• MARSHALL I, BURT RP, CHAPPLE CR: Noradrenaline con-tractions of human prostate mediated by ain-(aic-)ad-renoceptor subtype. Br.J. Pharmacol. (1995) 115:781–786.
   PubMed Web of Science ®Google Scholar
• GOETZ AS, LUTZ MW, RIMELE TJ, SAUSSY L: Charac-terization of alpha-l-adrenoceptor subtypes in human and canine prostate membranes. J. Pharmacol. Exp. Ther. (1994) 271:1228–1233.
   PubMed Web of Science ®Google Scholar
• MURAMATSU I, OSHITA M, OHMURA T, KIGOSHI 5, AKINO H, OKADA K: Pharmacological characterisation of al-ad-renoceptor subtypes in the human prostate; functional and binding studies. Br. J. Dol. (1994) 74:572–578.
   Google Scholar
• FORD APDW, ARREDONDO NF, BLUE DR, Jr., BONHAUS DW, KAVA MS, WILLIAMS TJ, VIMONT RL, ZHU QM, PFISTER JR, CLARKE BE: Do alpha-lA (alpha-1C) -adreno-ceptors (AR) mediate prostatic smooth muscle contrac-tion in man? Studies with a novel, selective alpha-1A-AR antagonist, RS 17053. Br. J. Pharmacol. (1995). In press.
   Google Scholar
• FAURE C, PIMOULE C, VALLANCIEN G, LANGER SZ, GRA-HAM D: Identification of al-adrenoceptor subtypes pre-sent in the human prostate. Life Sci. (1994) 54:1595–1605.
   PubMed Web of Science ®Google Scholar
• HEDLUND H, ANDERSSON KE, EK A: Preliminary effects of prazosin on the human bladder and urethra in vitro and in vivo. Proceedings of the IXth annual meeting on the International Continence Society. Rome, Italy (1979):90.
   Google Scholar
• ERI LM, TVETER KJ: a-Blockade in the treatment of symptomatic benign prostatic hyperplasia. J. Urol.(1995) 154:923–934.
   PubMed Web of Science ®Google Scholar
• Comprehensive review of clinical studies carried out with ai-adreno-ceptor antagonists in BPH.
   Google Scholar
• KENNY BA, NAYLOR AM. CARTER AJ, READ AM, GREEN-GRASS PM, WYLLIE MG: Effect of alpha-l-adrenoceptor antagonists on prostatic pressure and blood pressure in the anaesthetised dog. Urology (1994) 44:52–57.
   PubMed Web of Science ®Google Scholar
• SHIBASAKI M, SUDOH K, INAGAKI O, UCHIDA W, HONDAK: Effect of the optical isomers of YM-12617 on in-creased intra-urethral pressure induced by phenyle-phrine in anaesthetised dogs. J. Auton. Pharmacol. (1992) 12:263–268.
   PubMedGoogle Scholar
• TESTA R, SIRONI G, COLOMBO D, GRETO L, LEONARDI A: Rec 15/2739, a new aradrenoceptor antagonist selec-tive for the lower urinary tract: in vivo studies. Neur-ourol. Urodynamics (1994) 13:471–472.
   Google Scholar
• IACOVOU JW, DUNN M: Indorarnin - an effective new drug in the management of bladder outflow obstruc-tion. Brit. J. Urn!. (1987) 60:526–528.
   PubMedGoogle Scholar
• WETZEL JM, MIOA SW, FORRAY S, BORDEN LA, BRANCHEK TA GLUCHOWSKI C: Discovery of alw-adren-ergic receptor antagonists based on the L-type Ca2+ channel antagonist niguldipine. J. Med. Chem. (1995) 38:1579–1581.
   PubMed Web of Science ®Google Scholar
• GONG G, CHIU G, GLUCHOWSKI C, BRANCHEK TA, IIAR-TIG PR, PETTINGER WA, FORRAY C: aic-Adrenergic an-tagonists and orthostatic hypotension in the rat. FASEB J. (1994) 8:A353.
   Web of Science ®Google Scholar
• TESTA R, TADDEI C, POGGESI E, DESTEFANI C, COTEC-CHIA S, HIEBLE JP, SULPIZIO AC, NASELSKY D, BERGSMA D, ELLIS C, SWIFT A, GANGULY S, RUFFOLO RR, Jr., LEONARDI A: REC 15/2739 (SB 216,469) : A novel pros-tate selective alpha-l-adrenoceptor antagonist. Pharma-cology Communications (1995) 6:79–86.
   Google Scholar